LINC02126 is a potential diagnostic, prognostic and immunotherapeutic target for lung adenocarcinoma

Abstract

Background Adenocarcinoma has long been an independent histological class of lung cancer, which leads to high morbidity and mortality. We aimed to investigate the contribution of LINC02126 in lung adenocarcinoma. Methods RNA sequencing data and clinical information were downloaded. Diagnostic efficiency and survival analysis of LINC02126 were performed, followed by functional analysis of genes co-expressed with LINC02126 and differentially expressed genes (DEGs) in different LINC02126 expression groups. Tumor immune microenvironment (TIME) cell infiltration and correlation analysis of tumor mutation burden were performed in different LINC02126 expression groups. Results In lung adenocarcinoma, the expression level of LINC02126 was significantly decreased. Significant expression differences of LINC02126 were found in some clinical variables, including T staging, M staging, sex, stage, and EGFR mutation. LINC02126 had potential diagnostic and prognostic value for patients. In the low LINC02126 expression group, the infiltration degree of most immune cells was significantly lower than that in the high LINC02126 expression group. Tumor mutation burden level and frequency of somatic mutation in patients with low LINC02126 expression group were significantly higher than in patients with high LINC02126 expression group. Conclusions LINC02126 could be considered as a diagnostic, prognostic and immunotherapeutic target for lung adenocarcinoma.

Silencing of CD147 inhibits cell proliferation, migration, invasion, lipid metabolism dysregulation and promotes apoptosis in lung adenocarcinoma via blocking the Rap1 signaling pathway

“…Until now, molecular targeted therapy has achieved great advantages in the treatment of a myriad of cancer types [ 19 ]. Massive molecules have been proved to exhibit the potential in inhibiting the growth, progression, and metastasis of LUAD [ 20 – 23 ]. CD147 is a tumor-associated glycoprotein, which may also be a potential target for the treatment of LUAD.…”